NeuroCentrix TMS Clinic

NeuroCentrix TMS Clinic Neurocentrix is a private Melbourne mental health research centre established by directors Professor David Barton and Dr Peter Farnbach.

Both directors have extensive experience conducting mental health research and neuroscience clinical trials.

27/01/2022

Doctors generally view diagnoses as discrete, well-defined entities. You either have malaria, or you do not. You are pregnant, or you are not. There is no in-between. Settling upon one also rules out the others.

For example, if a CT on a patient with a splitting headache shows a brain tumour, that’s the diagnosis. The doctors don’t go hunting for other causes such as migraine or haemorrhage. While it’s possible for a patient to have two different causes of the same symptoms, in practice this scenario is so rare that it can safely be ignored. One diagnosis is more than enough.

When psychiatry entered the medical fold, it was assumed that the same model would apply. When a patient is diagnosed with say, depression or post-traumatic stress disorder, then that condition would explain their symptoms and guide their treatment. The patient would not have both depression and PTSD, or so the thinking went. Yet statistical analysis of mental health databases shows something entirely different, a finding that brings uncomfortable questions to the heart of psychiatry. Not only do most patients have more than one diagnosis, but each diagnosis makes every other diagnosis more likely. This means that a diagnosis of depression increases your chance of also having PTSD, schizophrenia, anorexia, bipolar … all of them. This is most certainly not how diagnosis is supposed to work.

If the same pattern held for medical illnesses, then diagnosing arthritis would mean you were more likely to have tuberculosis or diabetes. Having gallstones would increase the chances of haemophilia or herpes. In fact, having any illness at all would render you more likely to have any of the others!

This is precisely the opposite of how medical illnesses behave. When the CAT scan shows that the patient has a brain tumour, the diagnoses of migraine or cluster headaches are certainly not made more likely. They are ruled out. Yes, the patient may have many of the same symptoms, but that doesn’t matter, the diagnosis is brain tumour, end of story. Since the scenario is so preposterous, psychiatrists have begun to wonder what all this overlap means for the nature of mental illness.

The major difference between medical and psychiatric diagnosis is the handbook of mental illnesses, the Diagnostic and Statistical Manual, or DSM. Whereas a medical illness like pneumonia might be diagnosed by an x-ray and blood test, depression is defined by having a certain number of symptoms from a list in the DSM. These include a loss of appetite, insomnia, difficulty concentrating, and of course, depressed mood. You can immediately notice that these items on the checklist are broader and less well-defined than seeing a tumour on an x-ray, or a bug under a microscope. DSM criteria also have great potential for overlap. Take insomnia, for example, which could be caused by anxiety, depression, mania, psychosis, or something else entirely.

The only time when having one medical diagnosis makes having another more likely is when there is a clear causal link. For example, a brain tumour may cause a brain haemorrhage. The patient with both is not exceptionally unlucky; receiving two very unlikely diseases at once. He got unlucky with one, and it caused the other.

On the medical wards, it is common to see patients with a whole host of diagnoses. A typical medical admission may have diabetes, ischaemic heart disease, chronic obstructive airways disease, pneumonia and heart failure. Here the diagnoses are all interlinked, which is why they appear together so frequently. Diabetes leads to ischaemic heart disease, which leads to heart failure. Chronic obstructive airways disease leads to pneumonia, which in turns worsens the heart failure and the diabetes. At the beginning of it all may be smoking. The difference with psychiatry is that each medical illness is a clear category. Diabetes is elevated blood sugar; pneumonia is infected lungs. While they may be related in cause, they do not overlap in category.

The confusion in psychiatric diagnoses comes from overlap in both cause and category. Diabetes can lead to pneumonia, PTSD can lead to depression – so far so good. But both PTSD and depression can have the same symptoms of social withdrawal, negative thoughts, ruminating about the past, loss of appetite and energy, and many more. Deciding which symptoms are part of which diagnosis is not easy, and to make matters worse, there is no test to decide the issue. A physician can run a blood test or pull up an x-ray and actually see diabetes or pneumonia. Psychiatrists cannot ‘see’ depression. Even with the most advanced brain imaging, which is only used in research, PTSD and depression appear very much the same.

Different illnesses sharing the same symptoms partly explains why having one diagnosis increases the chance of having another. Another reason is that there are very few, if any, symptoms that occur in only one mental illness. Most crop up everywhere.

The cardinal symptom of schizophrenia, for example, is having auditory hallucinations. But these are also found in depression and mania. They may even appear in someone not mentally ill at all, but suffering from too much stress and not enough sleep. Since no one symptom can define schizophrenia, psychiatrists rely on others such as delusions or paranoia, but these too are found elsewhere. And that’s for schizophrenia, which is probably the most striking and clear-cut psychiatric diagnosis of them all, what Thomas Szasz called, “the sacred symbol of psychiatry”.

How to distinguish between depression, dysthymic disorder, and adjustment disorder? You can perhaps surmise that psychiatric diagnosis is very messy and complex, and wonder how psychiatrists ever decide anything at all.

Yet in practice, psychiatrists diagnose illnesses quickly and have little trouble drawing the line between well and unwell. A psychiatrist missing a major mental illness is very rare, at least as rare as a physician missing a major medical illness. While a patient with a clear brain tumour may not notice or show any symptoms for months, depression may be entirely obvious immediately.

Similarly, if a man suddenly tears off his clothes at work and declares himself to be the Witch King of Centrelink, there may be disagreement over whether the diagnosis is schizophrenia, bipolar disorder, or something else, but there is zero doubt that a diagnosis is warranted.

We can summarise these findings as follows:

Psychiatric diagnosis is easy in general, hard in specifics.
Distinguishing mental illnesses from normal is easy, hard from each other.
In other words, mental illnesses are real, but fuzzy. Psychiatrists have long understood this paradox, but until recently there has been little hope of a solution. Now they are turning to the burgeoning field of neuroscience to place psychiatry on a more secure footing. Studying genetics, brain imaging and neural pathways, researchers are slowly illuminating the physical basis of mental illnesses. Particularly striking is the finding that similar genes or brain changes are involved in several different conditions. For example, schizophrenia and autism share similar genetic and structural changes, which is exactly what their overlapping symptoms would predict.

What does this tell us about what mental illnesses really are?

One theory is that mental illnesses are best understood not as discrete entities but as a variety of overlapping dimensions that emerge from abnormalities in the brain. The nature and severity of these brain changes, and how they combine together, may ultimately explain how illnesses shade into one another. So instead of puzzling over whether a patient claiming to be Witch King of Centrelink has schizophrenia or bipolar disorder, a psychiatrist may diagnose his condition in terms of disturbance in mood, connection between thoughts, and reality perception.

Ideally each of these symptom types will relate to a particular neural circuit and an avenue for treatment. For example, the patient may be treated with lithium to stabilise his mood, a benzodiazepine to quell his anxiety, and olanzapine to streamline his disconnected thinking. As our imaging and understanding of the brain improves, there will be a tighter connection between the symptoms observed, the labels applied, and the treatments delivered. Just as occurs right now in physical medicine.

The reason why this approach is not already mainstream is that neuroscience lags far behind our knowledge of other organs, largely because the brain is vastly more complex. Here lies an irony, since we are fully aware of many of the brain’s operations – such as the choice to reach out for a glass – but how that choice comes about, and what permits us to experience both the choosing and the reaching, is a total mystery. Meanwhile we are unaware of processes of regulating blood pressure and digestion, yet researchers have detailed precisely how they happen. Brain science remains in its infancy, and stuck there with it is psychiatry.

Physical medicine was only recently in the same position. For centuries, doctors thought that malaria was from something in the air (hence the name, literally “bad air”) but only recently identified its precise relationship to the mosquito and the parasite it carries. Now doctors know the lifecycle of falciparum malaria, its effect on various organs, the best drugs to treat it, and the means to prevent it. Before then were treatments, such as quinine, or ‘Jesuit’s Bark’, that were discovered by chance and worked by processes unknown. The brain is so complex that when it comes to its afflictions, we remain at the stage of “bad air” and Jesuit’s Bark.

Yet there is reason for hope. Little more than a century ago, there was very little understanding of mental illness and almost no treatment. Since then, a variety of effective treatments have been discovered, and improving neuroscience is helping us understand why they work.

As we unravel the brain’s mysterious processes in ever more detail, better treatments will be discovered and not just by the fickle whim of chance. With genetics and imaging, researchers are beginning to design treatments tailored to specific brain circuits. This process goes both ways, as investigating the structures behind successful treatments can illuminate why they work, which then paves the way for even better treatments.

Psychiatry is still on the trail of its falciparum malaria, but the path is not as dark as it once was.

Neurocentrix is a private Melbourne mental health research centre established by directors Professor David Barton and Dr Peter Farnbach. Both directors have extensive experience conducting mental health research and neuroscience clinical trials.

12/10/2021

NeuroCentrix is now accepting referrals for the following services in Ballarat:

- Tele-health Psychiatric assessments with management plans
- Tele-health Psychological assessments and treatment
- Transcranial Magnetic Stimulation (rTMS) treatment
- Participation in a current research study on the efficacy of rTMS treatment in postpartum depression - a joint NeuroCentrix / Monash University study

TMS Treatment

TMS at NeuroCentrix is provided on a fee for service basis, at $185 per session. At present there is no Medicare rebate for TMS treatment. However, in 2021/2022 Budget Paper No. 2, the Federal Government announced funding to provide access to Medicare subsidised repetitive Transcranial Magnetic Stimulation for the treatment of medication resistant major depressive disorder.

A recent update from the Department of Health confirmed that the Medicare item numbers for rTMS treatment will commence on 1st Nov 2021.

NeuroCentrix offers a concierge service to handle funding applications for patients covered by the Department of Veterans Affairs, Traffic Accident Commission or Workcover, to assist patients' access to treatment.

Neurocentrix is a private Melbourne mental health research centre established by directors Professor David Barton and Dr Peter Farnbach. Both directors have extensive experience conducting mental health research and neuroscience clinical trials.

12/10/2021

Transcranial Magnetic Stimulation (TMS) has been used against depression for several decades, yet there remains deep scepticism among both patients and doctors over whether it really works.

Applying magnets to the brain might seem like a cross between a voodoo ritual and experiments in electricity in Victorian England. Either way it can look a lot like pseudoscience, especially since a recipient merely needs to sit there – no anaesthetic, no recovery time, no pain – and somehow the magnets do their work. Replace magnets with healing crystals and the picture would be complete.

When discussing TMS with psychiatrists unfamiliar with the technique, objections arise thick and fast. The most common viewpoint among the sceptical is that TMS is “unproven”, or “no better” than older methods.

When offered studies that show that TMS is superior – for example, for treatment-resistant depression – the reply quickly comes back that they “need more evidence” and “we’ll wait and see”. The prevailing opinion seems to be that only overwhelming experimental data will change their approach. Such a mindset is nothing new, and not necessarily bad.

Psychiatrists tend to be intensely sceptical of any new treatment, especially anything that departs from the usual mould of medication and psychotherapy. To be gung-ho about a treatment that ultimately reveals itself as useless is to be a dupe, a sucker, a bad psychiatrist. With too many empty promises filling TV and social media, to fall in with the hype is to jettison what sets a psychiatrist apart: training, experience, and clinical wisdom.

There have been too many failures to risk credulity, and too much to lose by being wrong. Far better to remain aloof and sceptical. At worst, the careful psychiatrist will be a little behind, and that is certainly superior to being naïve.

Meanwhile the public knows little about TMS at all. A quick straw poll of online opinions showed that while most have heard of TMS, few knew what it was for.

Those who could name depression assumed TMS was a treatment of last resort. Some thought of it as a new form of ECT and simply transferred their negative impressions. With patients unaware and doctors sceptical, adoption of TMS lags well behind its potential benefit.

To help address this gap, NeuroCentrix recently ran a study of TMS in depression, but with a twist. Almost all existing TMS studies have looked at a very select group of patients in a very specific setting, namely depression where other treatments have failed.

While these studies provide important evidence that TMS does work, they also reinforce the assumption that TMS is mostly for research or intractable cases. Patients with other conditions or using other treatments are excluded as much as possible from these trials, but in reality, most people who need treatment will have these features and many more.

Previous trials have also been restricted to the specific TMS protocol under investigation, with the same intensity, frequency, site and number of sessions. In practice these vary enormously. In the real world neither the patients nor the treatments fit the box that research decrees.

And so this study took all patients who had received TMS for whatever reason, and then assessed the effect retrospectively. Patients were neither handpicked nor excluded. The result was a large sample that represented real-life patients receiving TMS in a real-world setting.

The patients were assessed with rating scales at admission and discharge, and these numbers were analysed and compared. The total number of participants was 229, with 135 women and 94 men. They were of all ages, ranging from 19 to 89. Of the total number, 104 of the participants had more than one admission, and these further admissions were also included.

A review of the patient files indicated that each participant had been experiencing moderate to severe depressive symptoms, and major depressive disorder was the most common primary diagnosis. Yet depression alone is not the only way to be depressed, and many patients suffer depressive symptoms from another disorder. And so in this study featured a variety of conditions encompassing the whole range of psychiatric pathology, including alcohol abuse, ADHD, OCD, bipolar disorder, schizophrenia and personality disorders.

The only patients not included in the sample were those which could not be compared because of missing data, such as an incomplete discharge assessment.

Once all the statistical analyses were complete, the results of the study were clearly positive. Across all measures, symptoms of depression had decreased after TMS treatment. Not only did the results easily pass the test for statistical significance, but the improvement was substantial.

On average, a patient’s change in score was sufficient to move down one or two severity ranges, such as from severe to moderate or mild. Statistical analysis also revealed that the initial treatment produced a larger effect than subsequent treatments, which fits the expected law of diminishing returns.

Another important outcome of the study was that patients who recorded a mild severity of depression also benefited. Since most studies have involved patients with severe or treatment-resistant depression, this finding fills in a crucial gap in existing research.

Overall, the conclusion was unequivocal: an admission for TMS treatment has a significant antidepressant effect.

A potential criticism of the study is that patients may have improved from whatever treatment they had during their stay, not necessarily the TMS. Here is one drawback of the “real-world” approach.

By not excluding patients that receive other treatments, the benefit of these treatments would be lumped in with the TMS. However, this criticism is not as strong as it appears since any other treatment would usually already be in place before admission, and any treatment changes would be coincidental and insignificant compared to the reason for the admission, the TMS itself.

Changes to medication or psychotherapy, for example, do not require admission and could occur at any time, thus having no effect on the period under study. In fact, such changes would be more likely to occur apart from, rather than during, an admission for TMS.

Psychiatrists generally change only one treatment at a time, or there would be no way of knowing which change was responsible for the outcome. Such caution would be even more tightly applied when undertaking a novel and time-consuming treatment like TMS, since the understanding its impact would be crucial in deciding future management.

Meanwhile in the hypothetical cases where medications were changed during admission, any resulting benefit would likely not appear until well after discharge. A new antidepressant, for example, takes 4 to 6 weeks to reach its effect, which would accordingly not influence the assessment taken at discharge.

Another concern would be that patients might not leave until improved, and thus depression scores would naturally be better at discharge than admission. Ideally patients would improve during their stay, but this is not how admissions occur in practice.

Length of stay is usually capped regardless of outcome, and admissions for TMS are generally planned for a set period. The depression score at discharge therefore escapes this potential bias.

In fact, since discharge is often shortly after treatment, the discharge assessment may underestimate the benefit by assuming that any effect happens immediately.

Neuroscientific studies on the effects of TMS suggest a complex pathway that involves several much slower mechanisms, such as synaptic growth and restored neuronal connectivity. Together these processes fall under the term “neuroplasticity”, a phenomenon that takes weeks or even months to develop, and would certainly remain invisible to an assessment taken at discharge.

While the study cannot remain impervious to all criticisms, the size of the effect strongly suggests that overall the positive result is sound. The study indicates that TMS is effective for depressive symptoms over a large sample size which includes a variety of comorbidities, diagnoses, medications, lengths of stay, treating clinicians, protocols employed, and treatments delivered.

We can comfortably conclude that TMS is a viable and effective option for depressed patients in the real world.

Neurocentrix is a private Melbourne mental health research centre established by directors Professor David Barton and Dr Peter Farnbach. Both directors have extensive experience conducting mental health research and neuroscience clinical trials.

Address

1303 Heatherton Road
Melbourne, VIC
3174

Opening Hours

Monday 9am - 5pm
Tuesday 9am - 5pm
Wednesday 9am - 5pm
Thursday 9am - 5pm
Friday 9am - 5pm
Saturday 9am - 5pm
Sunday 9am - 5pm

Alerts

Be the first to know and let us send you an email when NeuroCentrix TMS Clinic posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to NeuroCentrix TMS Clinic:

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram